Last reviewed · How we verify
OXCARBAZEPINE
At a glance
| Generic name | OXCARBAZEPINE |
|---|---|
| Drug class | Anti-epileptic Agent [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
Common side effects
- Dizziness
- Diplopia
- Ataxia
- Vomiting
- Nausea
- Somnolence
- Headache
- Fatigue
- Abnormal vision
- Tremor
- Abnormal gait
- Rash
Serious adverse events
- Hyponatremia
- Status epilepticus
- Convulsions
- Maculopapular rash
Key clinical trials
- Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study (PHASE3)
- Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia (NA)
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (PHASE1)
- Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia (PHASE4)
- Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXCARBAZEPINE CI brief — competitive landscape report
- OXCARBAZEPINE updates RSS · CI watch RSS